These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 25109)

  • 41. Parkinson's disease. Dopamine may sustain toxic protein.
    Couzin J
    Science; 2001 Nov; 294(5545):1257-8. PubMed ID: 11701896
    [No Abstract]   [Full Text] [Related]  

  • 42. A study of brain dopamine sulfate levels in relation to free dopamine and homovanillic acid in Parkinson's disease.
    Sofic E; Riederer P; Wesemann W; Kienzl E; Eichinger K; Gsell W; Jellinger K
    J Neural Transm Park Dis Dement Sect; 1991; 3(4):265-71. PubMed ID: 1772579
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Decreased dopamine in the retinas of patients with Parkinson's disease.
    Harnois C; Di Paolo T
    Invest Ophthalmol Vis Sci; 1990 Nov; 31(11):2473-5. PubMed ID: 2243012
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The locus coeruleus: Another vulnerability target in Parkinson's disease.
    Oertel WH; Henrich MT; Janzen A; Geibl FF
    Mov Disord; 2019 Oct; 34(10):1423-1429. PubMed ID: 31291485
    [No Abstract]   [Full Text] [Related]  

  • 45. Somatic transposition in the brain has the potential to influence the biosynthesis of metabolites involved in Parkinson's disease and schizophrenia.
    Abrusán G
    Biol Direct; 2012 Nov; 7():41. PubMed ID: 23176288
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Endogenous dopamine release in Parkinson's disease.
    Rinne JO
    Lancet Neurol; 2003 Aug; 2(8):460-1. PubMed ID: 12878432
    [No Abstract]   [Full Text] [Related]  

  • 47. Parkinson's Disease: The Life Cycle of the Dopamine Neuron. September 18-20, 2002. Princeton, New Jersey, USA. Proceedings.
    Ann N Y Acad Sci; 2003 Jun; 991():1-360. PubMed ID: 12846968
    [No Abstract]   [Full Text] [Related]  

  • 48. Parkinson's disease, depression, and electroconvulsive therapy: a clinical and neurobiologic synthesis.
    Yudofsky SC
    Compr Psychiatry; 1979; 20(6):579-81. PubMed ID: 41677
    [No Abstract]   [Full Text] [Related]  

  • 49. [Neurochemical methods].
    Agid Y
    Rev Electroencephalogr Neurophysiol Clin; 1976; 6(4):444-6. PubMed ID: 14358
    [No Abstract]   [Full Text] [Related]  

  • 50. Biochemical pathophysiology of Parkinson's disease.
    Hornykiewicz O; Kish SJ
    Adv Neurol; 1987; 45():19-34. PubMed ID: 2881444
    [No Abstract]   [Full Text] [Related]  

  • 51. Mechanisms of Parkinson's disease.
    Br Med J; 1978 Apr; 1(6117):872-3. PubMed ID: 25109
    [No Abstract]   [Full Text] [Related]  

  • 52. [Parkinson's disease: neuro-anatomical, biochemical and pharmicotherapeutic aspects].
    Korf J; van Praagen HM; Lakke JP
    Ned Tijdschr Geneeskd; 1975 Sep; 119(36):1373-8. PubMed ID: 241026
    [No Abstract]   [Full Text] [Related]  

  • 53. [Parkinson disease and the neuronal dopamine uptake complex].
    Costentin J
    Ann Pharm Fr; 1995; 53(4):145-54. PubMed ID: 7574268
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Problems and future perspectives in the treatment of Parkinson's disease].
    Hens L; Hellemans J
    Tijdschr Gerontol Geriatr; 1982 Aug; 13(4):147-54. PubMed ID: 6127822
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Parkinson's disease and dementia.
    Agid Y; Ruberg M; Dubois B; Pillon B; Cusimano G; Raisman R; Cash R; Lhermitte F; Javoy-Agid F
    Clin Neuropharmacol; 1986; 9 Suppl 2():S22-36. PubMed ID: 2885087
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.